2008 - Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes

Lipscombe, Lorraine
April 2009
ACP Journal Club;4/21/2009, Vol. 150 Issue 4, p6
Academic Journal
The article reviews studies which have evaluated the impact of various oral diabetes medications in patients with type 2 diabetes. Oral metformin (MET), second-generation sulfonylureas (SFUs), thiazolidinediones (TZDs) or meglitinides have been evaluated for cardiovascular (CV) risk in type 2 diabetes. It was found that MET reduces risk for CV mortality but it is not differ from other drugs or placebo for CV morbidity.


Related Articles

  • Most SUs increase mortality compared with metformin.  // Diabetes Digest;2011, Vol. 10 Issue 4, p235 

    The article presents a study on the use of metformin and sulphonylureas (SUs) as treatment for people with sulphonylureas (SUs and associated mortality outcomes, in which study reveals that most SU monotheraphy increases mortality and cardiovascular (CV) risk.

  • Sulphonylurea monotherapy: Increased mortality and CV risk when compared with metformin?  // Diabetes Digest;2011, Vol. 10 Issue 4, p235 

    The article discusses the use of sulphonylurea (SU) monotherapy and metformin for people with type 2 diabetes wherein SU increases mortality and cardiovascular (CV) risk compared with metformin.

  • Early intensive anti-diabetic treatment may improve β-cell function.  // OB/GYN Clinical Alert;Dec2008 Clinical Briefs in Primary, Vol. 13, p23 

    The article reports on the study which examines the effects of early anti-diabetic treatments. Newly diagnosed type 2 diabetics with severe hyperglycemia have received intensive basal-prandial insulin therapy. Once good, glycemic control was administered and they were randomized to continued...

  • Perspective: General practice. Gadsby, Roger // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on a study which reveals the risks for cardiovascular disease (CVD) associated with the use of the glucose-lowering agent sulphonylurea.

  • Perspective: Prescribing advisors. Newland-Jones, Philip // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on the increased cardiovascular disease risk associated with the use of the glucose-lowering agent sulphonylurea. He believes that formulary developers and prescribing advisors should be aware of the risks of hypoglycaemia prior to prescribing sulphonylureas. He suggests...

  • Case Study--Managing newly diagnosed type-2 diabetes. Bostock-Cox, Beverley // Independent Nurse;6/4/2010, p1 

    The article presents a case study of a 58-year old man, Charlie, who underwent an axillary abscess and was diagnosed as a possible candidate for diabetes. Several changes in his lifestyle and dietary habits for reducing risks of cardiovascular diseases and a continuous monitoring routine were...

  • Long-term benefit from early blood glucose control. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Oct2008, Vol. 69 Issue 10, p553 

    The article reports on the result of the ten year follow-up data from the landmark United Kingdom Prospective Diabetes Study (UKPDS). It shows that intensive glucose lowering intervention such as sulfonylurea insulin group or metformin has a significant and lasting effects on major diabetes...

  • Insulin regimen in type 2 Diabetes Mellitus patients with poor glycemic control. Vintila, Vlad // Maedica - a Journal of Clinical Medicine;2007, Vol. 2 Issue 2, p156 

    The article reports on the impact of insulin formulation in a type two diabetes mellitus patients with poor glycemic control. It cites a clinical trial which compares the efficacy and safety of adding three insulin regimens to the treatment of patients with type two diabetes. It mentions that...

  • Rosiglitazone CV risk relative to metformin, sulfonylurea.  // Reactions Weekly;7/21/2007, Issue 1161, p5 

    The article discusses research being done on the link between rosiglitazone, metformin, sulfonylurea and cardiovascular (CV) events. The study examined data obtained from the Ingenix Research Database between July 2000 and December 2004 for patients with type 2 diabetes receiving monotherapy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics